Opinion

Video

Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer

The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
2 expert is featured in this series.
2 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.